Overview

Retinitis pigmentosa (RP) describes a group of genetic disorders that damage light-sensitive cells in the retina, leading to gradual vision loss over time as the cells die off. While the condition is classified as a rare disease, it is one of the most common inherited diseases of the retina, affecting between 1 in 3500 to 1 in 4000 Canadians.[1]RP is often referred to as an inherited retinal disease, meaning that it is passed along genetic lines and inherited from ones parents. Though it is usually diagnosed during childhood or adolescence, a minority of patients report symptoms later in life.

Specialized cells called photoreceptors are responsible for absorbing light and translating it into signals that are interpreted by the brainit is these essential cells that gradually die off as a result of RP. The cells come in two varieties: rod cells and cone cells. Rod photoreceptors are responsible for peripheral and night vision, while cone photoreceptors are responsible for central, high-acuity vision as well as detail and colour. Since it is the rod cells that are first damaged by RP, peripheral and night vision are affected during the early stages of the disease, followed by a narrowing of the visual field, often referred to as a progressive form of tunnel vision. The death of rod cells eventually affects the cone cells as well, leading to the loss of central vision and often resulting, during the later stages of the disease, in near or total blindness. The length of this process varies from individual to individual.

RP was originally considered a single disease, but after decades of researchincluding research funded by the FFBwe now know that there are several forms of RP, and that these forms involve mutations in any one of more than 64 different genes. The gene or genes affected determine the disease type and symptoms.

There are several different ways that RP can be inherited, which is usually described as the inheritance pattern. The different RP inheritance patterns include: autosomal dominant, autosomal recessive, and x-linked recessive. A genetic counsellor can talk with you about your family history and determine which of these patterns is associated with your vision loss. With this information, the genetic counsellor may be able to tell you more about how your condition will progress, and give you and your family information about the risks of vision loss for other family members. To learn more about genetic testing for RP, please consult the FFB resource Everything You Need to Know about Genetic Testing.

Typically, each person with RP only has damage in one pair of genes. Scientists have now identified more than 64 genes that can have mutations that cause RP. It is likely that mutations in more than 100 different genes will eventually be identified. Because so many RP-causing gene mutations are still unknown, there is about a 50:50 chance that genetic testing will provide a definitive result. Given your family history and the inheritance pattern of your RP, your genetic counsellor will be able to advise you about the likelihood that a genetic test will provide a definitive result.

Different genetic mutations can damage the retina or impair its function in different ways; for example, some mutations affect how the retina processes nutrients, while others damage the photoreceptors. Its important to identify the specific gene and mutation, because many treatments being developed for RP will be for particular genetic types.

Content on this page was written by Dr. Chad Andrews and Dr. Mary Sunderland, and was most recently updated on August 23, 2018. An earlier version of the content was approved by Dr. Jane Green and Dr. Bill Stell.

The most common early symptom of RP is difficultly seeing at night and in low-light conditionsthis is called nyctalopia or night blindness. The loss of peripheral vision is also a common first symptom, and is often experienced alongside nyctalopia. As RP progresses, peripheral vision slowly diminishes, resulting in a narrow field of view or tunnel vision. By age 40, many people with RP are legally blind, with a severely constricted field of vision, although many may retain the ability to read and recognize faces. Uncomfortable sensitivity to light and glare is common, as is photopsia (seeing flashes of light or shimmering). RP can also cause a loss of visual acuity (the ability to see clearly), but the onset is more variable. Some patients retain normal visual acuity, even when their vision is reduced to a small central island; others lose acuity much earlier in the course of disease. Eventually, however, most people with RP will begin to lose central vision and some will lose all light perception.

An ophthalmologist may suspect RP on the basis of a persons symptoms and the findings of a simple eye examination. Two tests are used to clarify the diagnosis:

Currently, there is only a single approved treatment for a very rare form of RP on the market in the United States: a gene therapy called Luxturna, which can halt vision loss and even restore some sight in individuals with a biallelic mutation of their RPE65 gene (manifesting as either RP or Leber congenital amaurosis). Though the number of patients with this mutation is small, the medical effectiveness of Luxturna and its materialization as a pharmaceutical product demonstrate that there is significant potential for gene therapy to treat other forms of RP in the future.

Read Our Story About The Approval of Luxturna

Clinical trials are essential to the scientific process of developing new treatments: they test the viability and safety of experimental drugs and techniques, called interventions, on human beings. While there is no guarantee that enrolling in a clinical trial will provide any medical benefit, some patients do experience positive results after receiving an experimental therapy.

Read Our Clinical Trials Guide

The website clinicaltrials.gov is a centralized database of clinical trials that are offered globally. But as the disclaimer on the sites home page states, there is no guarantee that a listed trial has been evaluated or approvedthe National Institutes of Health runs the site but does not vet its content. This means that there could be bogus or dangerous trials listed that are preying on patients. It is essential that you discuss a clinical trial with your ophthalmologist before enrolling, and that you pay close attention to enrollment criteria.

If you are interested in exploring what is available on the site you can click on the button below, which will take you to clinicaltrials.gov and initiate a search for trials relevant for patients living with RP.

CLINICAL TRIALS FOR Retinitis Pigmentosa

For individuals living with an inherited retinal disease (a disease caused by a genetic mutation), participation in a clinical trial could be a logical next-step (for a description of clinical trials, see above). But in Canada there is no centralized, guided mechanism for enrolling in a trial; with this in mind, the Foundation Fighting Blindness has developed a secure medical database of Canadian patients living with inherited retinal diseases: we call it the Patient Registry.

By enrolling in the Patient Registry, your information will become a part of this essential Canadian database that can be used to help connect you to a relevant clinical trial. The availability of relevant trials depends on a number of factors, so this tool provides no guarantees, but signing onto it will put you in a position to be connected to something appropriate. It is also a way of standing up and being counted: the more individuals enrolled in the Patient Registry, the better our chances of showing policymakers that there is a significant need for new treatments for inherited retinal diseases. The Patient Registry also helps to drive more sight-saving research!

You can begin the process of enrolling in the Patient Registry by clicking the button below.

Patient Registry Enrollment

The Foundation Fighting Blindness is committed to advancing the most promising sight-saving research, and has invested over $33 million into cutting-edge science since the organization was founded. Recognizing that science is tied to policy frameworks, the Foundation is also actively involved in health policy activities across Canada.

Many research groups are working to develop treatments and cures for RP. Experimental treatments can be divided into three broad categories:

Protective therapies aim to stop (or at least slow) the damage caused by genetic mutations. Often protective therapies are not specific to one mutation, but may benefit people with many types of RP. These include treatments to stop the process of photoreceptor death (apoptosis), as well as cell-derived therapies that aim to help photoreceptors survive.

Some protective therapies aim specifically to prevent the death of cone cells in RP and thus, the loss of central vision in later stages of the disease.

Corrective therapies aim to reverse the underlying genetic defect that causes vision loss. If these therapies are successful they might prevent a person who is treated when first diagnosed, from ever developing vision loss. Corrective therapies might also help slow the disease in people whose vision has already been affected, especially in the earlier stages. The corrective therapies being developed now are specific to certain forms of recessively inherited RP. Gene therapies, which replace a non-functioning gene, are one type of corrective therapy. Clinical trials of gene therapies for several types of RP are underway, and the results so far are encouraging.

Sight-restoring therapies are also a growing area of research success. These therapies are intended for people who have already lost all, or much, of their vision. Stem cell therapies aim to replace the retinas lost photoreceptors. There are promising early results with stem cell trials involving other retinal degenerative diseases; trials with RP are on the horizon. Retinal prosthetics, such as the Arugus II or Bionic Eye, use computer technology to generate vision. The Foundation Fighting Blindness helped to support the first Canadian trial of the Argus II and continues to work closely with health policy experts across Canada to ensure that patients who could benefit from the Argus II device have access to this innovative treatment. Drug and gene therapies are also being developed that may give non-photoreceptor nerve cells in the retina the capacity to sense light.

Thanks to our generous donors, we are funding ground-breaking research in these areas. Click on the button below to review the full list of FFB-funded projects:

FFB-FUNDED RESEARCH

On the right side of this webpage, you will find an updating list of stories that detail new research and health policy developments relevant for individuals affected by RP.

The page you are now on provides information on RP, but the Foundation Fighting Blindness has developed additional resources that can be helpful in plotting an optimal path through vision care. Below is a list of such resources, including information on genetic testing, clinical trials, Vision Quest (the FFBs in-person educational events), and more. The list will update as new resources are added.

Must-Read Resources Vision Quest Educational Series

We know that helpful resources related to your eye disease can be difficult to find. Vision care in Canada entails a complex web of services, programs, and instructions, and little of it is centralized. The information on this site represents our attempt at providing a comprehensive, centralized resource that offers guidance and information specific to your eye disease. Our goal is to help you find your optimal path through vision care in Canada, which is why we call this initiative Vision Care Pathways.

December 12th, 2018 by FFB Canada

Right now, over 1 million Canadians are living with blinding eye diseases and as vision fades, so too can hope. To date, donors of the Foundation Fighting Blindness (FFB) have contributed more than $32 million for vision research. And now, until the end of 2018, a generous supporter will match your gift up to a

Read More

November 13th, 2018 by FFB Canada

On Saturday, October 20, 2018, family and friends of the Celebres came together in support of one very special little boy. Nicholas Celebre was born with Usher syndrome,a condition that causes deaf-blindness and often balance issues. Born profoundly deaf, he was fortunate enough to get cochlear implants when he was 12 months old. He also

Read More

November 13th, 2018 by FFB Canada

Guest-written by Deborah Scott. Our daughter, Olivia was 5 years old when she was diagnosed with a blinding eye disease called retinitis pigmentosa (RP). It was difficult for us to comprehend what that diagnosis really meant. As a parent, you never get over the impact of learning that there is so much more to vision

Read More

See the original post here:
Retinitis Pigmentosa - The Foundation Fighting Blindness

Comments Off , Pings Off.